Heng-Huan Lee

Medicine & Life Sciences

1. ErbB Receptors 100%
2. Ligands 90%
3. Neoplasms 72%
4. Glycosylation 70%
5. Mantle-Cell Lymphoma 67%
6. Immunity 62%
7. Ribonucleases 58%
8. Human Herpesvirus 4 57%
9. Breast Neoplasms 55%
10. Ribonuclease 7 48%
11. T-Lymphocytes 47%
12. Triple Negative Breast Neoplasms 46%
13. Cell Nucleus Active Transport 45%
14. Chimeric Antigen Receptors 34%
15. Therapeutics 34%
16. Poly(ADP-ribose) Polymerase Inhibitors 34%
17. Agammaglobulinaemia Tyrosine Kinase 33%
18. Pancreatic Ribonuclease 31%
19. Trans-Activators 31%
20. Proteins 30%
21. Receptor Protein-Tyrosine Kinases 30%
22. Membranes 29%
23. Eph Family Receptors 29%
24. Basal Cell Carcinoma 29%
25. angiogenin 28%
26. PD protocol 28%
27. LDE225 26%
28. B7-H1 Antigen 25%
29. Phosphotransferases 25%
30. Immunotherapy 25%
31. antineoplaston A10 24%
32. SB 3CT compound 24%
33. Epidermal Growth Factor 24%
34. Biomarkers 24%
35. Phosphorylation 23%
36. Microfluidic Analytical Techniques 23%
37. EphA4 Receptor 23%
38. Methylation 23%
39. uracil phosphoribosyltransferase 23%
40. Tsg101 protein 22%
41. Hepatocellular Carcinoma 22%
42. Cyclin-Dependent Kinase 9 21%
43. Growth 21%
44. Positive Transcriptional Elongation Factor B 21%
45. Nuclear Envelope 21%
46. Ephrin-A4 20%
47. Ferroptosis 20%
48. Histone Deacetylase Inhibitors 20%
49. Cytosine Deaminase 19%
50. Protein-Arginine N-Methyltransferases 19%